Next™ BriefPhage Therapy and the Future of Antimicrobial Resistance Treatment
Buy Now
Meticulous Next™HealthcareNov 2026104 ppMRN-1373

Phage therapy Market Outlook 2026–2038: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

Brief ID: MRN-1373Format: PDF + Summary DeckDelivery: InstantHorizon: 12-yr horizonSignal: Emerging
Buy Now · $850
Adoption maturity (indexed)
Mainstream inflection: ~2034
Horizon: 2026–2038 · Signal: Emerging
12 yrs
Forward horizon
~2034
Mainstream inflection
Emerging
Signal strength

What This Brief Covers

This Meticulous Next™ brief examines phage therapy, the use of bacteriophages, viruses that infect bacteria, to treat infections that no longer respond to antibiotics. It tests how fast clinical trials and compassionate use move into approved products, and which participants capture value among phage developers, pharmaceutical partners, manufacturers and hospitals.

The first pivotal programme is now defined. In January 2026 Armata Pharmaceuticals reported that the FDA Center for Biologics Evaluation and Research reviewed its End-of-Phase 2 submission for AP-SA02, an intravenous phage cocktail for complicated Staphylococcus aureus bacteremia, and gave recommendations for a phase 3 superiority trial against standard-of-care antibiotics with clinical response and healthcare impact as primary endpoints. The programme carries a USD 26.2 million award from the US Department of Defense and a Qualified Infectious Disease Product designation, which can add five years of market exclusivity. The conclusion is that a phage product has a defined route to a pivotal trial, and the outcome of that trial sets the pace for the whole field.

Financing is the constraint. Armata reported cash of USD 14.1 million at the end of 2025, a net loss of USD 173.8 million for the year of which USD 105.8 million in the fourth quarter was a non-cash charge tied to a convertible loan, and an auditor paragraph expressing substantial doubt about continuing as a going concern. Innoviva, the largest shareholder, extended debt maturities to 1 June 2027 in January 2026, and the phase 3 start expected in the second half of 2026 depends on funding. The conclusion is that clinical progress in phage therapy depends on a small number of strategic backers, and the cost of a pivotal trial exceeds what small developers hold.

The wider field is broadening. TechnoPhage reported that its phase 2b trial of TP-102 in diabetic foot ulcers showed safety and tolerability, and Locus Biosciences uses engineered phages made on robotic platforms, holds a USD 3.3 million contract from the National Institute of Allergy and Infectious Diseases and partners with Viatris on ophthalmic uses. Antibiotic resistance causes roughly 5 million deaths a year, and the specificity of phages to bacterial strains, manufacturing standards and unclear approval pathways are named as the main barriers. The conclusion is that phage therapy is likely to complement antibiotics in resistant infections first, and approvals depend on trial design that handles strain specificity.

The brief treats phage therapy as an emerging signal with a twelve year horizon to 2038. It identifies which applications, regions and operators scale first and what each means for developers, pharmaceutical partners, manufacturers and hospitals. It is a focused 104-page decision brief that presents an indicative trajectory rather than a segmented market model.

Brief Snapshot
ParameterDetails
Forward horizon2026–2038 (12 years)
Emerging forcePhage therapy: clinical trials and compassionate use targeting resistant infections
Technology readinessOne phase 3 programme planned after FDA end-of-phase 2 review; phase 2 results in several indications; no approved phage product in the United States
Indicative market size & forecastThe phage therapy market, covering clinical-stage phage therapeutics, compassionate use programmes, phage production and testing services for resistant bacterial infections, is valued at USD 0.1–0.2 billion in 2026 and is projected to reach USD 2.33–4.66 billion by 2038, at a CAGR of 30%
Mainstream inflection~2034, when the first phage products are approved and used in routine care for resistant infections
Signal strengthFDA recommendations for a phase 3 trial, a USD 26.2 million US Department of Defense award and a Qualified Infectious Disease Product designation
Primary beneficiariesDevelopers with pivotal trial data; strategic backers; manufacturers of phage products
Brief length / format104 pages · PDF + executive summary deck · instant delivery

Understanding the Technology

Phage therapy uses bacteriophages to kill specific bacteria, either as fixed cocktails, as personalised preparations matched to a patient isolate, or as engineered phages and phage-derived proteins.

Selection depends on testing the bacterial isolate against a phage library, and production requires purification to biologic standards.

Delivery is intravenous, inhaled or topical, depending on the infection.

Uses are bloodstream infections, diabetic foot ulcers, respiratory infections in cystic fibrosis and eye and urinary infections.

The limits are strain specificity, manufacturing consistency, unclear approval pathways and developer cash. The period turns on whether pivotal trials show benefit over antibiotics.

Market Outlook

The phage therapy market, covering clinical-stage phage therapeutics, compassionate use programmes, phage production and testing services for resistant bacterial infections, is valued at USD 0.1–0.2 billion in 2026 and is projected to reach USD 2.33–4.66 billion by 2038, at a CAGR of 30%.

The 2026 base rests on clinical-stage programmes funded by grants and strategic investors, compassionate use programmes and phage production and testing services. Growth then follows pivotal trial results, first approvals and wider hospital programmes.

The forecast is sensitive to trial outcomes, developer financing and regulatory pathways. Regionally, North America leads on trials and defense funding, Europe on hospital and academic programmes, and Asia-Pacific on development in China and Australia.

Scenarios

The base case assumes the lead phase 3 trial starts by 2027 and at least one product is approved by 2032, giving the inflection in 2034. An accelerated case assumes a positive phase 3 result and several partnerships, bringing the inflection to 2031 and lifting the 2038 value to the top of the range. A delayed case assumes financing failures and trial setbacks, holding growth at the bottom of the range.

Factors Behind Growth

Growth drivers

  • Antimicrobial resistance burden.
  • First pivotal trials.
  • Government and defense funding.
  • Engineered and precision phage approaches.

Enablers

  • Qualified Infectious Disease Product incentives.
  • Compassionate use frameworks.
  • Academic phage banks and hospital programmes.
  • Partnerships with larger pharma companies.

Restraints and barriers

  • Small developers with limited cash.
  • Strain specificity and trial design.
  • Manufacturing standards.
  • Unclear approval pathways.

The Forces at Play

The direction of phage therapy is set by the need for treatments for resistant infections, regulatory pathways for adaptable biologics, genomics, engineering and automation, partnering among hospitals, biotechnology companies and governments, and funding and manufacturing cost.

Adoption Outlook

How the shift is likely to unfold across three time horizons.

Near term2026–2028
First pivotal trial

Phase 3 of the lead programme starts if funded, and other phase 2 trials report.

Mid term2028–2032
First regulatory decisions

The first phage products reach regulatory decisions and developers consolidate.

Long term2032–2038
Standard option for resistant infections

Phage therapy is a standard option for resistant infections.

Latest Strategic Developments

DateDevelopmentTypeSignificance
Mar 2024Armata Pharmaceuticals secures a USD 35 million credit facility from Innoviva at 14.0% interestFinancingFunds the development of AP-SA02 through the largest shareholder
Jan 2026Armata Pharmaceuticals reports that the FDA reviewed its End-of-Phase 2 submission for AP-SA02 and made recommendations for a phase 3 trialRegulatoryDefines the route to the first pivotal phage trial for bacteremia
Jan 2026Armata Pharmaceuticals amends its credit agreements with Innoviva and extends debt maturities to 1 June 2027FinancingExtends runway ahead of the planned phase 3 start
Mar 2026Armata Pharmaceuticals reports cash of USD 14.1 million at the end of 2025 and an auditor paragraph on going concernFinancingShows the funding need for a pivotal trial
Apr 2026Labiotech reports that AP-SA02 holds Qualified Infectious Disease Product designation and that the TP-102 phase 2b trial of TechnoPhage in diabetic foot ulcers showed safety and tolerabilityClinicalAdds regulatory incentives and a second phase 2 result

Key Players & Competitive Landscape

The key participants in phage therapy include Armata Pharmaceuticals, Inc., Locus Biosciences, Inc., BiomX Inc., TechnoPhage, S.A., Intralytix, Inc., SNIPR Biome ApS, Eligo Bioscience SAS, Phico Therapeutics Ltd, Micreos B.V., Phagelux, Inc., Phagos SAS, Fixed Phage Limited, BioNTech SE, Innoviva, Inc., Viatris Inc., GSK plc, Shionogi & Co., Ltd., Lonza Group Ltd, Charles River Laboratories International, Inc., Pfizer Inc., CARB-X, Wellcome Trust, Gates Foundation, University of California San Diego, Mayo Clinic, Eliava Institute, Hirszfeld Institute of Immunology and Experimental Therapy, Queen Astrid Military Hospital, Monash University, U.S. Department of Defense, Biomedical Advanced Research and Development Authority, National Institutes of Health, U.S. Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, National Medical Products Administration, Pharmaceuticals and Medical Devices Agency, Infectious Diseases Society of America, European Society of Clinical Microbiology and Infectious Diseases, World Health Organization, Biotechnology Innovation Organization and AMR Industry Alliance.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as phage therapy matures.

Armata Pharmaceuticals leads on the most advanced programme, Locus Biosciences, BiomX, TechnoPhage, Intralytix and SNIPR Biome lead on other clinical and engineered programmes, and Innoviva and Viatris are the main strategic backers. Competitive intensity is low in 2026 and rises as pivotal results arrive.

ArchetypeRepresentative playersPosition in 2026Outlook to 2038
Phage therapy developersArmata Pharmaceuticals, Locus Biosciences, BiomX, TechnoPhage, Intralytix, SNIPR Biome, Eligo Bioscience, Phico Therapeutics, Micreos, Phagelux, Phagos, Fixed Phage, BioNTechPhage cocktails, engineered phages and endolysinsDevelop products and run trials
Pharma, investors and strategic partnersInnoviva, Viatris, GSK, Shionogi, PfizerFunding, licensing and partnershipsFund programmes and license candidates
Manufacturers and testing providersLonza, Charles River LaboratoriesBiologic manufacturing and testingSupply manufacturing and quality testing
Hospitals, universities and fundersCARB-X, Wellcome Trust, Gates Foundation, University of California San Diego, Mayo Clinic, Eliava Institute, Hirszfeld Institute, Queen Astrid Military Hospital, Monash UniversityCompassionate use, phage banks and grantsTreat patients, hold phage libraries and fund research
Government agencies and regulatorsU.S. Department of Defense, Biomedical Advanced Research and Development Authority, National Institutes of Health, U.S. Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, National Medical Products Administration, Pharmaceuticals and Medical Devices AgencyFunding, review and approvalFund development and review products
Societies and industry bodiesInfectious Diseases Society of America, European Society of Clinical Microbiology and Infectious Diseases, World Health Organization, Biotechnology Innovation Organization, AMR Industry AllianceGuidelines and advocacySet clinical guidance and policy positions

Where value migrates.

In 2026 value sits with developers that have clinical-stage assets and strategic backers, because trial funding decides who survives. By 2032 it moves toward owners of approved phage products, because approvals carry pricing and exclusivity. By 2038 it settles in precision and engineered phage platforms. Margins hold for developers with exclusivity and funded manufacturing and narrow for those that depend on grant funding.

Who Will Win — and Why

The archetypes best positioned to capture value as the shift matures.

Developers with pivotal trial data

Firms with phase 3 data on a defined product.

Developers with funded manufacturing

Firms that can supply phage products at biologic standards.

Pharma companies with phage partnerships

Firms that back developers and hold rights to later products.

Regulatory Landscape

JurisdictionMilestoneIndicative timingEffect on adoption
FDA review of phage productsBiologic review of phage products by the Center for Biologics Evaluation and ResearchIn forceDefines trial requirements and manufacturing expectations
Qualified Infectious Disease Product designationUS incentive that adds market exclusivity for antibacterial productsIn forceAdds five years of exclusivity after approval
EU and national pathways for phage therapyHospital exemption and compassionate use rules in EuropeEmergingAllow personalised use outside trials
Defense and public health fundingGovernment awards for antibacterial developmentIn forceFund early clinical programmes
Manufacturing and quality requirementsPurity and stability standards for biologicsIn forceRaise the cost of scaling phage production

Investment Signals

The signals converge on a defined first pivotal programme with fragile financing. FDA recommendations for a phase 3 trial, a USD 26.2 million Department of Defense award and a Qualified Infectious Disease Product designation support growth, while developer cash of USD 14.1 million at the lead company, strain specificity and unclear pathways limit the pace.

Structural limits show where progress could slow: small developers with limited cash, strain specificity and trial design, manufacturing standards, and unclear approval pathways. The brief therefore tracks four indicators: pivotal trial starts and readouts, financing and partnerships, first regulatory decisions, and hospital phage programmes.

Bloodstream and device infections first, then chronic wounds and respiratory infections, then personalised and engineered approaches are the expected order of adoption.

Questions This Brief Answers

01What is phage therapy, and why does it matter?
02What is the market size in 2026, and what is the forecast to 2038?
03What do the clinical programmes indicate?
04What factors are driving growth, and what barriers remain?
05Which key participants are active, and which archetypes are positioned to win?
06What are the latest developments?
07How will trial results and financing shape adoption between 2026 and 2038?
08What should developers, hospitals and investors do now?

Strategic Implications

  • Phage therapy developers: secure funding for pivotal trials, design trials that handle strain specificity and build manufacturing.
  • Hospitals and clinicians: build isolate testing and access programmes and join trials.
  • Pharma and defense buyers: decide which programmes to back and set supply plans.
  • Policy makers and regulators: clarify pathways for adaptable phage products and expand incentives.
  • Investors: treat pivotal trial results, financing, partnerships and first approvals as the leading indicators.
Analyst Perspective

"Phage therapy has a defined route to a pivotal trial for the first time. Whether anyone can pay for that trial is the more pressing question."

Lead Foresight Analyst
Biotechnology & Life Sciences · Meticulous Next™

Table of Contents

Access & Licensing

A focused foresight brief, priced to circulate. Every option is delivered instantly and backed by analyst support.

Single Brief
$850
One named user
Full PDF brief
Executive summary deck
One named user
Free outlook update
★ Most Popular
Team License
$1,350
Up to 10 users
Access for 2–10 users
Internal sharing rights
30-minute analyst briefing
Enterprise
$2,050
Organization-wide
Organization-wide access
Unlimited users
Priority analyst access
Custom extracts
Included with
every brief
Analyst-reviewed foresightMulti-signal validationInstant deliveryFree outlook updates

Frequently Asked Questions

Search Market Intelligence

Search across reports, blogs, press releases, and industries